A Single-arm Study of Upfront Chemotherapy With Radiation Therapy (CRT) Followed by Chemotherapy in Localized Esophageal Adenocarcinoma

Duke University

Summary

The goal of this trial is to learn if adding consolidative chemotherapy to routine chemoradiation can better control both local recurrence and metastasis and reduce the need for surgical intervention.

Eligibility

Age range: 18+ years
Sex: All
Healthy volunteers: No

Detailed criteria

Inclusion Criteria: * Subject must be able to provide study specific informed consent prior to study entry * Must be newly diagnosed, histologically proven diagnosis of adenocarcinoma of the thoracic esophagus or gastroesophageal junction (Siewert I-II); * Stage II-IVA, excluding T4b, according to the American Joint Committee on Cancer (AJCC) 8th edition; * Complete history and physical examination within 21 days of signing consent; * Staging whole-body FDG-PET/CT (fluorodeoxyglucose-positron emission tomography/computed tomography) scan with or without contrast (preferred) or chest/abdominal…

Interventions

Drug
FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin)
Modified-FOLFOX-6 or FLOT (Fluorouracil, Leucovorin, Oxaliplatin, Docetaxel)

Location

Duke University Medical Center
Durham, North Carolina
RadOnc-Clinical_Trials@dm.duke.edu (919) 668-3726

A Single-arm Study of Upfront Chemotherapy With Radiation Therapy (CRT) Followed by Chemotherapy in Localized Esophageal Adenocarcinoma

Summary

Eligibility

Interventions

Location

Compensation

Run this study?

Details

Conditions